{"DataElement":{"publicId":"2005410","version":"4","preferredName":"CTC Adverse Event Hypersensitivity Description Grade","preferredDefinition":"in CTC category Allergy/Immunology, assessment of the severity of an allergic reaction or hypersensitivity adverse event using a graded scale.","longName":"CTC_AE_HYPERSEN_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2192359","version":"2","preferredName":"CTC Adverse Event Hypersensitivity Description","preferredDefinition":"information related to the description or grade of CTC adverse event allergic reaction.","longName":"CTC_AE_HYPERSEN_DESC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2660716","version":"1","preferredName":"Hypersensitivity Description ","preferredDefinition":"Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.:Description; a statement that represents something in words.","longName":"C3114:C25365","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypersensitivity","conceptCode":"C3114","definition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E73C82-CB7F-5882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2045A13-89C2-ADB5-E040-BB89AD4374D9","latestVersionIndicator":"Yes","beginDate":"2004-11-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017610","version":"3","preferredName":"CTC Adverse Event Hypersensitivity Grade","preferredDefinition":"in CTC category Allergy/Immunology, assessment of the severity of an allergic reaction or hypersensitivity adverse event using a graded scale.","longName":"CTC_AE_HYPERSEN_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C425833D-CFCF-587F-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C425833D-CFD1-587F-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Transient flushing or rash; drug fever <38 C (<100.4 F)","ValueMeaning":{"publicId":"2566298","version":"1","preferredName":"Transient flushing or rash; drug fever <38 C (<100.4 F)","longName":"2566298","preferredDefinition":"Transient flushing or rash; drug fever <38 C (<100.4 F)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D007-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C425833D-CFD3-587F-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Rash; flushing; urticaria; dyspnea; drug fever >=38 C (>=100.4 F)","ValueMeaning":{"publicId":"2566297","version":"1","preferredName":"Rash; flushing; urticaria; dyspnea; drug fever >=38 C (>=100.4 F)","longName":"2566297","preferredDefinition":"Rash; flushing; urticaria; dyspnea; drug fever >=38 C (>=100.4 F)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D006-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C425833D-CFD5-587F-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Symptomatic bronchospasm, with or without urticaria parenteral medication(s) indicated; allergy-related edema/angioedema; hypotension","ValueMeaning":{"publicId":"2566296","version":"1","preferredName":"Symptomatic bronchospasm, with or without urticaria parenteral medication(s) indicated; allergy-related edema/angioedema; hypotension","longName":"2566296","preferredDefinition":"Symptomatic bronchospasm, with or without urticaria parenteral medication(s) indicated; allergy-related edema/angioedema; hypotension","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D005-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C425833D-CFD7-587F-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"anaphylaxis","ValueMeaning":{"publicId":"2562825","version":"1","preferredName":"anaphylaxis","longName":"2562825","preferredDefinition":"anaphylaxis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C276-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C425833D-CFD9-587F-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C425833D-CFCB-587F-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"2005410","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"CTCAE3_1010000_GRADE","type":"COG Form Element","context":"CTEP"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"}],"ReferenceDocuments":[{"name":"CTC Adverse Event Allergic re","type":"Preferred Question Text","description":"CTC Adverse Event Allergic reaction/hypersensitivity (including drug fever) Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Allergic reaction Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"},{"name":"Grade","type":"Alternate Question Text","description":"Grade","url":null,"context":"NHLBI"},{"name":"Grade","type":"Application Standard Question Text","description":"Grade","url":null,"context":"NHLBI"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C4259B73-8DC4-587D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"KUMMEROA","dateModified":"2018-05-03","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}